Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
Shankara Paneesha, MD FRCP FRCPath
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Applications of Emerging Data in Resectable NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.